Does the Drug Shortage White Paper Fall Short?
FDA Law Blog: Biosimilars
APRIL 8, 2024
To address the underlying causes of shortages, the White Paper suggests that the creation (by Congress) of two programs that link inpatient hospital purchasing and payment decisions to supply chain resilience practices would better incentivize investments in mature manufacturing practices.
57 
Let's personalize your content